Key result
The abstract outlines the rationale for the RAAFT-2 trial evaluating radiofrequency ablation versus antiarrhythmic drugs for paroxysmal atrial fibrillation, but reports no clinical results.
RCT
RAAFT-2 rationale published without results; leaves first-line ablation efficacy versus drugs unresolved pending trial data.
Radiofrequency ablation (RFA) for the treatment of paroxysmal Atrial Fibrillation (pAF) has a class 1 indication in patients who have not tolerated or responded to antiarrhythmic medications. Antiarrhythmic medications (AAM) are, however, limited not only by modest efficacy, but also by significant side effects. Discontinuation rates for AAM range from 11-40% in trials. The RAAFT-2 trial evaluates the use of RFA as a first line treatment for pAF compared to optimal pharmacological management (1).
No takes yet. Share an insight, caveat, or question.
Kaba et al. (2014) conducted an RCT in paroxysmal Atrial Fibrillation (pAF). Radiofrequency ablation (RFA) vs. optimal pharmacological management (antiarrhythmic medications) was evaluated. The abstract outlines the rationale for the RAAFT-2 trial evaluating radiofrequency ablation versus antiarrhythmic drugs for paroxysmal atrial fibrillation, but reports no clinical results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: